Dyadic Netherlands, a subsidiary of Dyadic International, a company developing enzyme and protein products for several industries including the biofuels industry, has announced that they have entered into a research agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and EnGen Bio, Inc. As part of the agreement, Sanofi Pasteur will fund collaborative research at Dyadic Netherland’s research and development facility in Wageningen, The Netherlands, which will utilize Dyadic’s proprietary and patented C1 Platform Technology for certain vaccine applications.

Dyadic Netherland’s General Manager, Dr. ir. Wim van der Wilden will guide the research with collaboration from Dr. Mark Alfenito, the President and CEO of EnGen Bio, an early stage biopharmaceutical company based in Redwood City, California. The research is anticipated to be completed in six to twelve months. All other terms of the research collaboration are confidential.

Mark Emalfarb, President and CEO of Dyadic added, “We are very pleased to have the opportunity to work with Sanofi Pasteur and EnGen Bio to further demonstrate the utility of our C1 technology for certain vaccine applications.